Investor confidence in Takeda stock price forecast is linked to upcoming FDA reviews for new therapies. Analysts highlight a possible ¥4,600 resistance test if approvals hit in FY2024, adding momentum to trading volumes. Public companies currently own 11% of Ovid Therapeutics stock. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together. Exclusive news, data and analytics for financial market professionals Takeda stock price forecast for Q3 2024 suggests a moderate bullish trend, with analysts targeting ¥4,300–¥4,500 per share, supported by strong oncology sales. Institutional investors note improving margins and a robust dividend yield near 3.8%.